FDA and MFDS regulatory evidence frameworks, side by side

The US Food and Drug Administration (US FDA) and the Korean Ministry of Food and Drug Safety (MFDS) are reading the same underlying exosome and growth-factor literature and arriving at meaningfully different regulatory conclusions. That asymmetry is not a story of one agency being right and the other being careless — both are serious regulators administering thoughtful frameworks — but the asymmetry has practical consequences for any American patient considering a Seoul protocol, and it deserves a more careful reading than most American medical commentary or Korean clinic marketing tends to give it. I write this regulatory-evidence page as Daniel Park, a Korean-American writer based in California, with a recurring American audience and a deliberate aim of laying out the evidence each agency weighs without flattening the contrast into advocacy for either side. The page reads the FDA's published position on exosome products as biologics requiring premarket approval, the MFDS framework permitting licensed cell-processing facilities to supply bio-actives to clinics under documented quality systems, and the underlying evidence base — drawn from PubMed-indexed primary literature — that both agencies are reading. A patient who finishes this page should understand why the same molecule is treated differently in Seoul and in San Diego, what each agency's evidence threshold actually is, and how to read clinic marketing in either jurisdiction against the regulatory background. The companion [evidence base review](/stem-cell-evidence-base/) and [Korea vs US clinics](/stem-cell-vs-us-clinics/) pages cover the literature and pricing geography in more detail.

Two agencies, two evidence thresholds, one molecule

The starting observation is structural: the FDA and MFDS are not disagreeing about what exosomes are at a molecular level, and they are not disagreeing about the underlying preclinical and human-subjects literature in any fundamental way. Both agencies have access to the same PubMed-indexed primary studies, the same mechanistic cell-biology data, and the same set of small-to-medium-sample human-subjects reports on exosome microneedling and adjunct IV protocols. What they disagree on is the regulatory threshold that should be applied before a cell-derived bio-active product is permitted in clinical use. The FDA applies a biologic-drug framework that, by design, demands a high evidence threshold — randomised controlled trials, defined chemistry-manufacturing-controls, and a formal premarket approval process — before a cell-derived product can be marketed for therapeutic claims. MFDS applies a framework that, while serious in its quality-system oversight of licensed cell-processing facilities, permits clinical use of defined bio-active products at an earlier evidence stage than the FDA's biologic-drug pathway would. Neither framework is unreasonable on its face. The FDA framework reflects an agency-philosophical preference for premarket evidence certainty; the MFDS framework reflects a preference for clinical access to a regulated product class while the evidence base continues to mature. An American patient evaluating Seoul access is essentially crossing from the first framework into the second, and that is what the page that follows lays out in concrete terms.

What the US FDA position actually says about exosomes

The US FDA position on exosome products, when read in primary form on the agency's published guidance and consumer-safety communications, is more specific than most American patient-facing summaries suggest. The agency's December 2019 public safety notification and subsequent communications characterise exosomes derived from cells as biologic products that, when marketed or administered for therapeutic claims, fall under the agency's biologic-drug authority. The practical implication is that an exosome product cannot be lawfully marketed in the United States for therapeutic use outside one of two regulatory pathways: an Investigational New Drug (IND) application authorising clinical trials, or a Biologics License Application (BLA) authorising marketing of an approved product. As of the agency's currently published guidance, no exosome product has been approved under either pathway for the aesthetic and dermatologic uses that are routine in Korean clinical practice. The FDA position does not, importantly, claim that the underlying mechanistic literature on extracellular vesicles is invalid; the agency's communications acknowledge the active research interest in the molecular class. What the position claims is that the literature has not yet produced the evidence package the agency's biologic-drug pathway requires for marketing approval. American practices that administer exosome-labelled products outside an IND or a BLA are, in the agency's published characterisation, operating in concerning regulatory territory. American patients reading clinic marketing for domestic exosome services should weigh the agency's position against the marketing claims with proportionate seriousness.

What the MFDS framework actually permits, and on what evidence

The MFDS framework on cell-derived bio-actives — exosomes, growth factors, conditioned media — distinguishes between investigational cell therapy, which sits under an entirely separate and more demanding regulatory pathway, and the narrower category of bio-active products that licensed cell-processing facilities can manufacture and supply to clinics for in-clinic application. The latter category is not unregulated; it operates under MFDS-supervised quality systems, licensed-facility oversight, and documented manufacturing specifications. What the framework permits, that the FDA framework does not, is the clinical use of these bio-actives at an evidence stage where the human-subjects literature consists predominantly of small-to-medium-sample studies rather than large randomised trials. The MFDS reading is, in essence, that the mechanistic literature establishing extracellular-vesicle signalling biology, combined with the moderate human-subjects evidence for skin-quality outcomes, and combined with the quality-system oversight of licensed facilities, is sufficient to permit clinical use under a regulated product class — while the evidence base continues to mature toward the larger-trial tier. The framework is administered seriously: a licensed Korean clinic should be able to document which licensed facility processed the bio-active, under what specifications, and with what concentration profile. Patients should ask for this disclosure in writing, and the better Seoul practices will provide it without prompting. The honest reading of the MFDS position is not that the agency has lower standards than the FDA — it is that the agency has different standards, weighted toward earlier clinical access of a regulated and quality-supervised product class.

The underlying evidence base both agencies are reading

Both regulators are reading a peer-reviewed literature base, indexed on PubMed, that has matured substantially since 2020 but that still sits short of the large-randomised-trial tier the FDA's biologic-drug pathway would prefer. The mechanistic literature on extracellular-vesicle signalling — fibroblast collagen synthesis, keratinocyte response, endothelial migration, inflammation modulation — is large and well-established; the cell-biology case for exosome bio-activity is not in serious scientific dispute. The human-subjects literature on dermatologic applications — exosome bio-active delivered via microneedling for skin texture, elasticity, and fine-wrinkle reduction — consists predominantly of single-centre, small-to-medium-sample, open-label or single-blinded studies, mostly from Korean dermatology research groups and increasingly from international groups working with research-grade preparations. The reported effect sizes are real but moderate, the responder distribution is uneven, and the durability data is still maturing toward the multi-year follow-up tier. The human-subjects literature on systemic IV protocols is meaningfully thinner than the dermatologic literature, consisting largely of case series and small clinical studies. Both agencies are weighing this same evidence package and arriving at different regulatory conclusions because their evidence thresholds for clinical use are calibrated differently, not because they are reading different literatures. The fact that a Korean patient receives an MFDS-regulated bio-active that an American patient cannot receive under the FDA framework reflects regulatory-threshold asymmetry, not Korean physicians having access to better evidence than American physicians do.

What clinical use looks like under each framework

Under the MFDS framework, clinical use of exosome and growth-factor bio-actives in Seoul aesthetic and dermatologic practice is, in regulatory terms, routine. A senior Gangnam, Cheongdam, or Apgujeong dermatologist administering exosome bio-active via microneedling or RF micro-channelling for skin texture and elasticity is operating within a regulated product class, with a documented supply chain and a defined clinical protocol — exosome IV adjunct wellness protocols are administered under the same regulatory framework, though the evidence literature for IV applications is thinner than for dermatologic applications and patients should weigh that asymmetry. Under the FDA framework, clinical use of exosome-labelled products outside an IND or a BLA is, in the agency's published characterisation, not authorised; American practices administering such products are operating in territory the agency has explicitly described as concerning, and the variability in product source, concentration, and supply-chain documentation across such practices is part of what concerns the agency. An American patient flying to Seoul is, in regulatory terms, exiting the second framework and entering the first; an American patient receiving exosome treatment in California or Texas under a non-IND, non-BLA pathway is operating in a regulatory environment the agency has flagged as concerning. The contrast is not subtle, and patients should understand it clearly before making either decision. The decision a patient makes is theirs; the regulatory context should not be opaque.

Reading clinic marketing in either jurisdiction against the regulatory background

Clinic marketing in both jurisdictions tends to elide the regulatory contrast in ways patients should learn to read against. Seoul clinic marketing for international audiences sometimes implies that the bio-active class is more universally accepted than the cross-jurisdiction regulatory picture would suggest; American clinic marketing for exosome services sometimes implies that the underlying biology is more contested than the cell-biology literature supports, or alternatively that the product is more regulatorily settled than the FDA's published position would suggest. Neither set of marketing claims is the honest read. The honest read is that the underlying mechanistic literature supports the bio-active class as plausible and clinically active; the human-subjects literature supports moderate clinical effect in responder populations with effect sizes that justify clinical use in a regulated framework; the MFDS framework permits clinical use under documented supply-chain oversight; the FDA framework does not yet permit marketing of comparable products outside the IND-or-BLA pathway; and patients evaluating either jurisdiction should weigh the regulatory background alongside the marketing claims, not let the marketing claims substitute for the regulatory background. The [evidence base review](/stem-cell-evidence-base/) on this directory lays out the underlying literature in more detail for patients who want to read primary sources before making a decision.

What an American patient should ask before booking Seoul, given the regulatory contrast

Given the regulatory background laid out above, an American patient evaluating a Seoul protocol should ask a more specific set of questions than they might otherwise. Which licensed Korean cell-processing facility supplied the bio-active the clinic is administering, and can the clinic provide written documentation of the facility's MFDS regulatory status; what is the source-cell type — adipose-derived, umbilical-cord-derived, bone-marrow-derived — and what is the concentration profile of the product as delivered; what is the senior physician's licensure, regenerative-medicine experience, and how many patients on the relevant protocol has the practice treated; what is the foreign-patient-attraction registration status of the clinic under KHIDI; and what is the written aftercare protocol the clinic will provide for the post-procedure period and the patient's return to the United States. The clinic that answers these questions in writing without resistance is operating in a manner consistent with the MFDS regulatory framework as it is designed to function; the clinic that resists written disclosure is, in regulatory terms, a clinic the framework would not endorse. American patients accustomed to American clinic disclosure norms should not assume that Korean clinics will provide less disclosure than American practices would — the better Seoul practices provide more — but should ask explicitly, and should expect written documentation as a matter of course.

“Two serious agencies are reading the same evidence base and arriving at different regulatory conclusions because their evidence thresholds for clinical use are calibrated differently. That is the structural fact an American patient should understand before booking Seoul, before booking domestically, or before dismissing either option as illegitimate.”

Frequently asked questions

Why does the FDA treat exosome products as biologic drugs requiring approval?

The FDA's published framework classifies cell-derived products administered for therapeutic claims as biologics under the agency's biologic-drug authority. The agency's position requires either an Investigational New Drug (IND) authorisation for clinical trials or a Biologics License Application (BLA) for marketing. The framework reflects an agency-philosophical preference for premarket evidence certainty before clinical use is permitted.

Does MFDS hold cell-derived bio-actives to a lower standard than the FDA?

Different, not lower. MFDS oversees a documented quality system for licensed cell-processing facilities supplying bio-actives, with traceable batch records, defined source-cell specifications, and concentration profiles. The threshold for clinical use is calibrated earlier in the evidence-maturation curve than the FDA's biologic-drug pathway, but the quality-system oversight of licensed facilities is serious.

Is the underlying scientific literature contested between the two agencies?

No. Both agencies are reading the same PubMed-indexed primary literature on extracellular-vesicle signalling biology and human-subjects dermatologic outcomes. The disagreement is on the evidence threshold required before clinical use is permitted, not on the validity of the underlying mechanistic and human-subjects studies.

What pathways do exist for exosome work in the United States?

An FDA-authorised IND enables investigational clinical use in registered trials; a BLA-licensed product enables routine marketing once the agency has approved the application. As of the agency's currently published guidance, no exosome product has been approved under the BLA pathway for the aesthetic and dermatologic uses routine in Korean practice.

How can I verify a Korean clinic's regulatory chain?

Ask in writing which licensed Korean cell-processing facility supplied the bio-active, what its MFDS regulatory status is, what the source-cell type and concentration profile of the product is, and what the clinic's foreign-patient-attraction registration status under KHIDI is. The better Seoul practices provide this documentation as a matter of course.

Is the price differential between Seoul and US protocols a quality differential?

No. It is a regulatory differential. MFDS-supervised manufacturing in Korea operates at scale within a regulated market, producing competitive clinic pricing for the bio-active itself. The US restricted pathway, where products would require IND or BLA approval, structurally produces higher costs where comparable products are accessible at all.

If the FDA has concerns, why does Korea permit the same molecule?

Because the two regulatory frameworks weigh evidence thresholds and quality-system oversight differently. MFDS permits clinical use of a regulated and quality-supervised bio-active class while the larger-trial evidence base continues to mature. The FDA prefers premarket evidence certainty through the IND-or-BLA pathway before clinical use is permitted. Both reflect legitimate regulatory philosophies.

What does this mean for an American patient practically?

It means an American patient receiving exosome treatment in Seoul under the MFDS framework is accessing a regulated product class with documented supply-chain oversight, while a comparable product administered in the United States outside an IND or a BLA is operating in regulatory territory the FDA has explicitly flagged as concerning. The patient's decision belongs with them; the regulatory context should be understood clearly.